Latest epilepsy Stories
WOODCLIFF LAKE, N.J., Aug. 20, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset Seizures: Results of Randomized Global Phase III Study 305," and "Perampanel, A Selective, Non-Competitive AMPA Receptor Antagonist, as Adjunctive Therapy for Refractory Partial-Onset Seizures: Interim Results from Phase III, Open-Label Extension Study 307," were published today in the online...
ATLANTA, Aug. 15, 2012 /PRNewswire/ -- Since its launch in March 2012, the "My Four Words" project has reached thousands of people with empowering messages of living beyond the boundaries of epilepsy. Now, representatives from UCB and the Epilepsy Advocate(TM) program are inviting participants at the Epilepsy Foundation of Georgia's 29(th) Annual Magnolia Run and Walk for Epilepsy to contribute to the movement and raise awareness of epilepsy by sharing their four-word stories....
SCHAUMBURG, Ill., Aug 8, 2012 /PRNewswire/ -- Wellness Center USA, Inc. (OTCQB: WCUI), a Schaumburg, IL based healthcare and nutraceutical company, today announced the consummation of its CNS-Wellness LLC (CNS) acquisition. CNS is a Tampa, FL based cognitive neuroscience company specializing in the treatment of brain-based behavioral health disorders without the use of drugs. These disorders range from affective (emotional) and stress-related problems such as; anxiety,...
Scientists at the Gladstone Institutes have discovered that an FDA-approved anti-epileptic drug reverses memory loss and alleviates other Alzheimer's-related impairments in an animal model of the disease. Scientists in the laboratory of Lennart Mucke, MD, who directs neurological research at Gladstone, conducted the research on mice genetically modified to simulate key aspects of Alzheimer's disease. In the study, they show how levetiracetam—a drug commonly prescribed for patients who...
HOUSTON, Aug. 7, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that the company will report financial results for the first quarter ended July 27, 2012, of its fiscal year ending April 26, 2013, on Tuesday, August 28, 2012, before regular market trading hours. The company will conduct a conference call to discuss those results on the same day at 8:00 AM Central Time (9:00 AM Eastern Time). Fiscal Year 2013 First Quarter Results Conference Call InstructionsThe...
Diet Doc hCG Weight Loss Program Aims to Lower Blood Pressure Through an Easy-to-Follow Ketogenic Diet utilizing a personalized diet plan found to be effective in burning fat and reducing blood pressure. San Jose, CA (PRWEB) July 13, 2012 The ketogenic diet has long been known to treat a variety of health conditions ranging from epilepsy, to diabetes, to even anxiety. However, recent studies have shown the diet is very effective in lowering blood pressure as well. The American Heart...
The Consumer Justice Foundation, a for-profit corporation whose team of professional consumer advocates provides free online educational resources to the public concerning the potential dangers of using certain prescription medications, has a Web site whose URL can be found at http://www.depakotebirthinjury.com. The Consumer Justice Foundation hereby alerts the public of a Depakote birth defects lawsuit that was filed in Illinois against Abbott Laboratories, the manufacturer of Depakote...
Lawrence LeBlond for redOrbit.com - Your Universe Online At least three genetic mutations found in the human brain have been linked to enlarged brain size (megalencephaly) and a number of disorders, including cancer, epilepsy and autism, according to new research led by Seattle Children’s Research Institute. The mutations were found in the genes AKT3, PIK3R2 and PIK3CA. The mutations were also linked to vascular disorders and skin growth disorders, said the researchers. The study,...
LOS ANGELES, July 2, 2012 /PRNewswire/ -- Today NeuroSigma, Inc., a Los Angeles-based medical device company, announced that it received ISO 13485: 2003 certification, indicating that it operates a Quality Management System for the design, manufacturing and distribution of its external Trigeminal Nerve Stimulation (eTNS(TM)) system for the treatment of neurological and neuropsychiatric disorders. This certification is an important first step in a two-step process towards CE Mark...
VANCOUVER, June 26, 2012 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of Robert Chisholm as Chief Financial Officer ("CFO") of the company effective June 26, 2012. Mr. Chisholm will remain on the Anavex Board of Directors, on which he has served since May 2011. A veteran finance and administration executive with more than 25 years of experience, Mr. Chisholm has significant expertise in corporate finance, strategic business...
